reports
DBV Technologies annonce son intention de modifier le ratio d'ADS
DBV Technologies annonce son intention de modifier le ratio d'ADS Châtillon, France, le 17 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), une société biopharmaceutique au stade clinique spécialisée dans les options de traitement des allergies alimentaires et d'autres conditions immunologiques dont les besoins médicaux ne sont pas satisfaits (« la Société »), a annoncé aujourd'hui son intention de modifier le ratio de ses American Depositary Shares ("ADS") par ra...
DBV Technologies Announces Plan to Implement ADS Ratio Change
DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares (the “ADS Ratio”), nominal value €0.10 (ten cents) per share, from the...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Sharad Kumar S.P
- Wim Lewi
DBV Technologies Announces Results of its 2024 Combined General Meetin...
DBV Technologies Announces Results of its 2024 Combined General Meeting Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen,...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte...
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Châtillon, France, le 16 mai 2024 DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2024 Toutes les résolutions proposées à l’Assemblée Générale ont été adoptées DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), (la « Société »), une entreprise biopharmaceutique de stade clinique spécialisée dans le développement d’options de traitement des allergies alimentaires et autres affections immunologiques ayant d’importants besoins médicaux non satisfaits, a tenu...
Information mensuelle relative au nombre total de droits de vote et d’...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 16 mai 2024 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / NasdaqEuronext Compartiment : B Code ISIN : FR0011341205Nasdaq : NBTXBloomberg : NANO:FPReuters : NANO.PASite web : DateNombre total d’actions composant le capital socialNombre total de droits de voteTotal théorique1Total exerçable230 avril 202447 133 32848 903 29848 881 180 En applic...
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, May 16, 2024 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2April 30, 202447,133,32848,903,29848,881,180 According to the arti...
Inventiva annonce la recommandation positive du quatrième DMC de l’étu...
Inventiva annonce la recommandation positive du quatrième DMC de l’étude clinique NATiV3 Phase III avec lanifibranor dans la MASH/NASH Le Data Monitoring Committee recommande sur la base d’une revue planifiée des données de sécurité que l’étude clinique de Phase III continue sans modification du protocole actuel.L’évaluation réalisée par le DMC est basée sur l’examen non masqué des données de sécurité provenant de plus de 900 patients randomisés dans les cohortes principale et exploratoire, incluant respectivement plus de 360 et plus de 80 patients ayant été traités pendant plus de 48 et 72...
Inventiva announces the positive recommendation of the fourth DMC of t...
Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.The patient who exp...
NANOBIOTIX to Announce First Quarter Operational and Financial Update ...
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024 Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST PARIS and CAMBRIDGE, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that it will report its financial and operational results for the first quarter of 2024 on May 22, 2024, before the US and EU markets open. This release...
NANOBIOTIX publiera ses résultats financiers et opérationnels du premi...
NANOBIOTIX publiera ses résultats financiers et opérationnels du premier trimestre 2024 le 22 mai 2024 Conférence téléphonique et diffusion en direct sur Internet le 22 mai 2024 à 14 h 00 CEST / 8 h 00 EDT PARIS et CAMBRIDGE, Mass., 15 mai 2024 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique pour élargir les possibilités de traitement des patients atteints de cancer, annonce aujourd’hui qu’elle publiera, le 22 mai 2024, avant l’ouvertu...
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Pha...
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that the U.S. Food and Drug Administration (“US FDA”) issued a Study May Proceed Letter for a randomized Phase 2 study evaluating NBTXR3 for t...
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament...
NANOBIOTIX annonce l'acceptation par l'Agence américaine du médicament, la FDA, d'un protocole pour une nouvelle étude randomisée de Phase 2 évaluant NBTXR3 pour les patients atteints d'un cancer du poumon de stade trois PARIS et CAMBRIDGE, Mass., 14 mai 2024 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur la physique pour élargir les possibilités de traitement des patients atteints de cancer, annonce aujourd’hui que l’Agence américaine du médicamen...
- Guy Sips
- Jacob Mekhael
- Sharad Kumar S.P
- Wim Hoste
- Jacob Mekhael
Inventiva Additional NATIVE data supportive of lanifibranor's benefit ...
Yesterday, Inventiva announced the publication of additional results from the phase 2 (NATIVE) trial of lanifibranor in MASH (previously NASH), which are in line with previously reported benefits on cardiometabolic outcomes, leading the stock to trade +7% intraday. We believe the results continue to support lanifibranor's positioning in MASH, and look forward to the last patient first visit (expected by 1H24) in the phase 3 (NATiV3) trial. We reiterate our BUY rating and € 10 TP.
- Aurore Aventin (IDMidCaps)
Hexaom - Downbeat start to the year in line with forecasts
Significant downturn in CMI activity in Q1 in line with our expectations, while renovation logically shows greater resilience2024 guidance confirmed, and a low point in sales seems to have been definitively reached last yearOur forecasts for 2024 and beyond are maintainedValuation multiples still low despite the nearly 15% YTD rebound in the share priceBUY opinion and target price of €35/share maintained
Quadient S.A. - Monthly information on number of shares and voting rig...
Quadient S.A. - Monthly information on number of shares and voting rights Monthly information on number of shares and voting rights of Quadient S.A. In accordance with article 223.11 of Autorité des Marchés Financiers’ (French Securities and Investment board) General Regulations Ordinary shares - ISIN: FR0000120560 As at 30 April 2024Total number of shares34,468,912Theoretical total number of voting rights34,468,912Net total number of voting rights34,259,216 For more information, please contact: Catherine Hubert-Dorel, Quadient+33 (0)1 45 36 30 56Caroline Baude, Quadient+33 (0)1 45 36 31...
Inventiva announces the publication in Nature Communications of additi...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG) levels), systemic inflammation (hs-CRP, ferritin), hepatic steatosis and diastolic blood pressure.Among the patients who had prediabetes at study entry and were treate...
Inventiva annonce la publication dans Nature Communications de résulta...
Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité Des améliorations ont été observées au niveau de la résistance à l'insuline (taux d'insuline, HOMA-IR), du métabolisme lipidique (triglycérides, HDL-cholestérol, apolipoprotéines), du contrôle de la glycémie (HbA1c, taux de glucose à jeun), de l'inflammation systémique (hs-CRP, ferritine), de la stéatose hépatique et de la pression artérielle diastolique...
DBV Technologies to Participate in Upcoming Investor Conferences
DBV Technologies to Participate in Upcoming Investor Conferences Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced Daniel Tassé, Chief Executive Officer, will deliver a company presentation at two investor conferences in May. Citizens JMP Life Scie...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.